ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2013
Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan.
Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Pooled it
- Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.Emerging infectious diseases · 2020Pooled it
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Doxycycline treatment for drug-resistantFrontiers in medicine · 2026Article
- Macrolide-Resistant Mycoplasma pneumoniae Infections among Children before and during COVID-19 Pandemic, Taiwan, 2017-2023.Emerging infectious diseases · 2024Article
- Characteristics of theAntibiotics (Basel, Switzerland) · 2023Article
- Mycoplasma pneumoniae among Hospitalized Patients with Acute Respiratory Tract Infections in an Indian Tertiary Care Hospital: an Underreported Health Problem.Microbiology spectrum · 2022Article
- Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-ResistantJournal of clinical medicine · 2022Review
- Clinical Characteristics of Macrolide-RefractoryJournal of clinical medicine · 2022Article
- Drug-Induced Esophageal Ulcer in Adolescent Population: Experience at a Single Medical Center in Central Taiwan.Medicina (Kaunas, Lithuania) · 2021Article
- Consideration in treatment decisions for refractory Mycoplasma pneumoniae pneumonia.Clinical and experimental pediatrics · 2021Article
- Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.Emerging infectious diseases · 2021Article
- Clinical Efficacy of Doxycycline for Treatment of Macrolide-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.Journal of clinical microbiology · 2019Article
- Value of serumExperimental and therapeutic medicine · 2017Article
- Mycoplasma pneumoniae from the Respiratory Tract and Beyond.Clinical microbiology reviews · 2017Review
- Role of Serum Mycoplasma pneumoniae IgA, IgM, and IgG in the Diagnosis of Mycoplasma pneumoniae-Related Pneumonia in School-Age Children and Adolescents.Clinical and vaccine immunology : CVI · 2017Article
- Community-Acquired Pneumonia in the Asia-Pacific Region.Seminars in respiratory and critical care medicine · 2016Review
- A Compendium for Mycoplasma pneumoniae.Frontiers in microbiology · 2016Review
- Epidemiology of Mycoplasma pneumoniae Infections in Japan and Therapeutic Strategies for Macrolide-Resistant M. pneumoniae.Frontiers in microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to estimate the prevalence of macrolide-resistant Mycoplasma pneumoniae in Taiwan and to compare the clinical courses of pediatric patients with macrolide-resistant (MR) M. pneumoniae and macrolide-susceptible (MS) M. pneumoniae infection. Patients were among the children admitted to Chang Gung Children's Hospital with mycoplasmal pneumonia between February and December 2011. Detection for macrolide resistance was performed after informed consent was obtained. We retrospectively reviewed medical records and compared the clinical courses of two groups of patients of 73 children enrolled into our study. The rate of macrolide resistance in M. pneumoniae was 12.3 %. Longer hospital stay was observed in the MR patients than MS patients [median, 7 days vs. 5 days (P = 0.019)]. Clinical features or radiographic or laboratory findings are not helpful to differentiate MR from MS mycoplasmal pneumonia. Early diagnosis of MR mycoplasmal pneumonia is crucial for the best management of these patients and obviates the need for extensive etiological searches of these nonresponding cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.